3 days popular7 days popular1 month popular3 months popular

Comorbidities Taken Into Account Before Prostate Biopsy

Health urologists and health policy experts report in a new study that two written assessments that identify existing – the patient-reported Total Illness Burden Index for (TIBI-Cap) and the physician-reported Charlson Comorbidity Index – can successfully target prostate patients who would not benefit from biopsy to discover possible cancer.

The authors say that by taking comorbidities into consideration, it may not be necessary for men to have . This study does not preclude the use of PSA screening, but it does set the stage for a new and much more targeted strategy for biopsy choice. The desired result – fewer unneeded biopsies and fewer invasive, side-effect-producing treatments.

It’s estimated that around 20 percent of men would be in such a high-risk category (for death or hospitalizations) and should consider not having a biopsy.

Study results appear in early online version of the journal Cancer.

The corresponding author is Dr. Atreya Dash, who led the study of 104 patients. Co-authors include Drs. , John Billimek and Sheldon Greenfield of the Health Policy Research Institute at UC Irvine. Greenfield is an Institute of Medicine member and co-chaired an IOM study on comparative effectiveness research.

“Before prostate biopsy, providers should assess the number and severity of the patient’s comorbid conditions to discuss whether proceeding with biopsy or therapy is likely to be beneficial,” Dash said.

Source

University of California – Irvine